Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD

3.21  -0.17 (-5.03%)

After market: 3.21 0 (0%)

Fundamental Rating

5

ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While ORGO has a great profitability rating, there are some minor concerns on its financial health. ORGO has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

ORGO had positive earnings in the past year.
In the past year ORGO had a positive cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in 4 of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

The Return On Assets of ORGO (-1.65%) is better than 91.62% of its industry peers.
ORGO has a better Return On Equity (-2.65%) than 92.34% of its industry peers.
The Return On Invested Capital of ORGO (1.68%) is better than 93.40% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.16%.
The 3 year average ROIC (6.08%) for ORGO is well above the current ROIC(1.68%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.65%
ROE -2.65%
ROIC 1.68%
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

ORGO's Profit Margin has declined in the last couple of years.
ORGO's Operating Margin of 2.20% is amongst the best of the industry. ORGO outperforms 93.58% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO's Gross Margin of 75.29% is amongst the best of the industry. ORGO outperforms 85.20% of its industry peers.
ORGO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 2.2%
PM (TTM) N/A
GM 75.29%
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
The number of shares outstanding for ORGO has been increased compared to 1 year ago.
Compared to 5 years ago, ORGO has more shares outstanding
The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.82 indicates that ORGO is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.82, ORGO is doing good in the industry, outperforming 74.33% of the companies in the same industry.
ORGO has a debt to FCF ratio of 16.51. This is a negative value and a sign of low solvency as ORGO would need 16.51 years to pay back of all of its debts.
The Debt to FCF ratio of ORGO (16.51) is better than 92.69% of its industry peers.
ORGO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ORGO (0.21) is worse than 70.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 16.51
Altman-Z 2.82
ROIC/WACC0.18
WACC9.28%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.09 indicates that ORGO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.09, ORGO is doing worse than 64.35% of the companies in the same industry.
ORGO has a Quick Ratio of 2.74. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a worse Quick ratio (2.74) than 67.20% of its industry peers.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 2.74
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.00% over the past year.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -30.66% yearly.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 1.37%.
The Revenue has been growing by 17.50% on average over the past years. This is quite good.
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5YN/A
EPS Q2Q%350%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Sales Q2Q%6.12%

3.2 Future

ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.51% yearly.
ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y-265.75%
EPS Next 2Y-38.15%
EPS Next 3Y33.51%
EPS Next 5YN/A
Revenue Next Year5.41%
Revenue Next 2Y3.47%
Revenue Next 3Y4.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 29.18, the valuation of ORGO can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 94.65% of the companies listed in the same industry.
ORGO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 209.80, the valuation of ORGO can be described as expensive.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 90.73% of the companies in the same industry.
ORGO is valuated expensively when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 29.18
Fwd PE 209.8
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 96.61% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ORGO is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 103.67
EV/EBITDA 13.93
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

ORGO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 33.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.15%
EPS Next 3Y33.51%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (2/21/2025, 8:00:02 PM)

After market: 3.21 0 (0%)

3.21

-0.17 (-5.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners50.15%
Inst Owner Change-97.44%
Ins Owners30.6%
Ins Owner Change-12.24%
Market Cap403.59M
Analysts82
Price Target5.1 (58.88%)
Short Float %12.92%
Short Ratio14.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)3.75%
Max Revenue beat(2)4.78%
Revenue beat(4)3
Avg Revenue beat(4)1.21%
Min Revenue beat(4)-10.41%
Max Revenue beat(4)6.7%
Revenue beat(8)4
Avg Revenue beat(8)0.41%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)8
Avg Revenue beat(16)1.79%
PT rev (1m)0%
PT rev (3m)6.38%
EPS NQ rev (1m)16.67%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)61.76%
Revenue NQ rev (1m)2.49%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.07%
Valuation
Industry RankSector Rank
PE 29.18
Fwd PE 209.8
P/S 0.89
P/FCF 103.67
P/OCF 29.06
P/B 1.45
P/tB 1.71
EV/EBITDA 13.93
EPS(TTM)0.11
EY3.43%
EPS(NY)0.02
Fwd EY0.48%
FCF(TTM)0.03
FCFY0.96%
OCF(TTM)0.11
OCFY3.44%
SpS3.62
BVpS2.22
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.65%
ROE -2.65%
ROCE 2.72%
ROIC 1.68%
ROICexc 2.26%
ROICexgc 2.67%
OM 2.2%
PM (TTM) N/A
GM 75.29%
FCFM 0.86%
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
ROICexc(3y)8.72%
ROICexc(5y)N/A
ROICexgc(3y)11%
ROICexgc(5y)N/A
ROCE(3y)9.81%
ROCE(5y)N/A
ROICexcg growth 3Y-44.87%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.73%
ROICexc growth 5YN/A
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
F-Score5
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 16.51
Debt/EBITDA 2.13
Cap/Depr 59.55%
Cap/Sales 2.2%
Interest Coverage 1.78
Cash Conversion 51.8%
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 2.74
Altman-Z 2.82
F-Score5
WACC9.28%
ROIC/WACC0.18
Cap/Depr(3y)255.15%
Cap/Depr(5y)209.48%
Cap/Sales(3y)6.6%
Cap/Sales(5y)5.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5YN/A
EPS Q2Q%350%
EPS Next Y-265.75%
EPS Next 2Y-38.15%
EPS Next 3Y33.51%
EPS Next 5YN/A
Revenue 1Y (TTM)1.37%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Sales Q2Q%6.12%
Revenue Next Year5.41%
Revenue Next 2Y3.47%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y-55.42%
EBIT growth 3Y-22.3%
EBIT growth 5YN/A
EBIT Next Year134.74%
EBIT Next 3Y40.69%
EBIT Next 5YN/A
FCF growth 1Y-40.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.33%
OCF growth 3Y78.13%
OCF growth 5YN/A